Please ensure Javascript is enabled for purposes of website accessibility

Amgen Q4 Earnings Results: 2 Things to Hate and 2 Things to Like

By Keith Speights - Feb 3, 2018 at 10:33AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

And a couple of things to wonder about, too.

Amgen (AMGN -0.21%) shareholders sort of got used to mixed results in 2017. While the company's revenue growth was anemic at best, Amgen posted respectable earnings-per-share growth after adjusting for special items. This was the case for the first three quarters of the year. 

But the results weren't mixed when Amgen provided an update on its fourth-quarter performance after the market closed on Thursday. And the news wasn't positive. While there were a couple of things for investors to certainly hate about the biotech's fourth-quarter results, there were also a couple of things to like. 

2 thumbs up and 2 thumbs down

Image source: Getty Images.

Things to hate No. 1: sinking revenue

Amgen continued to experience an overall decline in revenue in the fourth quarter. Total revenue dropped 3% year over year to $5.8 billion. It's easy to spot why.

Sales for Amgen's best-selling product, Enbrel, fell 13% from the prior-year period to $1.37 billion. The autoimmune disease drug faces fierce competition. In addition, Amgen has lowered pricing on Enbrel. The combination of lower unit demand and reduced pricing provided a double whammy.

The company's No. 2 drug, Neulasta, didn't help offset Enbrel's decline. Sales for the drug, which helps prevent infection after chemotherapy treatment, were basically flat year over year.

Things to hate No. 2: flat earnings growth

Speaking of flat and things to hate, Amgen announced flat earnings growth in the fourth quarter. The biotech reported adjusted earnings per share of $2.89 for the period, exactly the same amount that it posted in the fourth quarter of 2016. And the full story is actually worse.

Amgen's adjusted net income dropped 3% year over year to $2.1 billion. Stock buybacks helped the company avoid an adjusted earnings-per-share decline. On a GAAP basis, Amgen reported a net loss in the fourth quarter of nearly $4.3 billion, significantly worse than the $1.9 billion in earnings during the prior-year period. However, the loss stemmed from a one-time $6.1 billion charge related to the impact of U.S. corporate tax reform.

Things to like No. 1: huge cash stockpile

Now for some good news. Amgen continues to generate strong cash flow. Even though revenue and adjusted net income fell in the fourth quarter compared to the prior-year period, the company reported free cash flow of nearly $2.9 billion, just as it did in the fourth quarter of 2016.

This free cash flow helped Amgen increase its cash stockpile to nearly $41.7 billion, including cash, cash equivalents, and marketable securities. Most of this amount was made outside of the U.S. The tax reform legislation recently implemented in the U.S. will allow Amgen to repatriate offshore cash at a reduced tax rate. 

Things to like No. 2: more share repurchases and higher dividends on the way

Perhaps the best news for shareholders is that Amgen plans to return plenty of cash to them in a couple of ways. The biotech's board of directors approved an additional $10 billion for stock repurchases on top of the existing $4.4 billion in share repurchase authorization as of Dec. 31, 2017. Last year, Amgen bought back $3.1 billion worth of its stock.

Amgen also announced a dividend increase of 15%. This marks the company's seventh consecutive year of dividend hikes. Since the initiation of its dividend program in 2011, Amgen has increased its dividend payout by a whopping 371%. Its dividend now yields 2.76%. 

Things to wonder about

I think there are also several things for Amgen investors to wonder about. One such item is whether or not Amgen CEO Bob Bradway's optimism about the company's long-term growth drivers is warranted.

At the J.P. Morgan Healthcare Conference held in early January, Bradway listed five drugs that he predicted would enable Amgen to grow in the future. Only one of them is currently a blockbuster with solid sales growth -- osteoporosis drug Prolia. However, the jury is still out on cholesterol drug Repatha, multiple myeloma drug Kyprolis, migraine drug Aimovig, and Amgen's biosimilars.

There are reasons for Bradway's optimism, though. Repatha's product label now reflects the drug's potential to prevent heart attack and stroke. Kyprolis could receive a helpful label update showing positive overall survival results, with an FDA decision expected by April 30, 2018. Aimovig should win approval in May. 

Perhaps the biggest thing to wonder about, however, is what Amgen might do on the acquisitions front. Bradway acknowledged at the J.P. Morgan conference that there is "potential for doing some attractive business development." The right deal could give investors something else to like about Amgen -- and maybe even love. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$244.85 (-0.21%) $0.52
JPMorgan Chase & Co. Stock Quote
JPMorgan Chase & Co.
JPM
$116.38 (-0.80%) $0.94

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.